VALENCIA, Spain, Sept. 25, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 8th Annual Chardan Genetic Medicines Conference, being held September 30-October 1, 2024, in New York, NY.
Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference.
About ARTHEx BiotechARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company’s lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
|
Company Contact. |
Investor and Media Contact |
|
Frédéric Legros |
Amy Conrad |
|
Executive Chairman and CEO |
Juniper Point |
|
+33679495790 |
+1 858-366-3243 |
SOURCE ARTHEx Biotech
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+Newsrooms &Influencers
9k+Digital MediaOutlets
270k+JournalistsOpted In